Company intelligence / Profile preview

Presidio Pharmaceuticals

San Francisco, California, United Statespresidiopharma.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

Presidio Pharmaceuticals has developed a pipeline of small-molecule antiviral drugs targeting hepatitis C and HIV. Its lead HCV program includes PPI‑461, an NS5A inhibitor that showed positive results in a Phase 1b trial for chronic hepatitis C genotype 1 patients—demonstrating good tolerability and significant reductions in HCV RNA levels. Other programs include compounds targeting the HCV NS5B polymerase and investigational therapies for HIV. Some pipeline assets have been discontinued or are pending further development.[6][8]

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeAntiviral therapeutics
Industry: Biotech

Drug pipeline

3 assets

PPI-383

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Presidio Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presidio Pharmaceuticals.

Explore the full profile